Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Catrin Fischetti"'
Publikováno v:
BMJ Open Quality, Vol 12, Iss 2 (2023)
Background Poor monitoring of anticoagulants is a significant area of patient safety. It can lead to the dichotomous risk of haemorrhage/clotting without appropriate counselling and monitoring. While healthcare professionals may be familiar with the
Externí odkaz:
https://doaj.org/article/e561fd603b2e4716ab1d1c555b025882
Autor:
David Taylor, Ian J. Osborne, Anna Sparshatt, Gwenllian Hughes, Fahima Amin, Olubanke Dzahini, Catrin Fischetti
Publikováno v:
Journal of Psychopharmacology. 31:1564-1569
Second generation antipsychotic long-acting injections have a greater cost than older depots. Their cost-effectiveness has yet to be established. We conducted a non-interventional, observational, follow-up of patients prescribed aripiprazole long-act
Autor:
Adrian Thomas, David Taylor, Victoria Cornelius, Delia Bishara, Catrin Fischetti, Anna Sparshatt
Publikováno v:
Acta Psychiatrica Scandinavica. 120:97-101
To evaluate naturalistic use of risperidone long-acting injection (RLAI) and its effect on healthcare resource use.Mirror-image comparison of healthcare resource use for 3 years before RLAI initiation and 3 years after.In total, 211 of 277 patients c
Autor:
Delia Bishara, Catrin Fischetti, Anna Sparshatt, Victoria Cornelius, David Taylor, Arwel Thomas
Publikováno v:
The Journal of Clinical Psychiatry. 70:196-200
To evaluate outcomes of clinical use of risperidone long-acting injection (RLAI) and determine factors predicting continuation with treatment.This prospective, 3-year follow-up of consecutive patients started on treatment with RLAI in normal clinical
Publikováno v:
Acta psychiatrica Scandinavica. 116(6)
Objective: To evaluate the effectiveness of aripiprazole in clinical practice. Method: Prospective follow-up of patients consecutively prescribed aripiprazole in an acute mental health unit. Retrospective analysis of outcome from casenotes. Results:
Publikováno v:
The Journal of clinical psychiatry. 68(7)
Background: Clozapine is uniquely effective in refractory schizophrenia, but treatment attrition is high. There has been minimal formal study of the outcomes of stopping clozapine, beyond published observations of the time period immediately after ce